Adjuvant capecitabine, docetaxel, cyclophosphamide,and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial

Heikki Joensuu, Pirkko Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola-Vuorinen, Minna Tanner, Riitta Kokko, Johan Ahlgren, Päivi Auvinen, Outi Paija, Leena Helle, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Marjo Pajunen, Raija Asola, Paula Poikonen, Mika Leinonen, Vesa Kataja, Petri Bono, Henrik Lindman

Research output: Contribution to journalArticleScientificpeer-review

80 Citations (Scopus)

Abstract

Purpose: Capecitabine is an active agent in the treatment of breast cancer. It is not known whether integration of capecitabine into an adjuvant regimen that contains a taxane, an anthracycline, and cyclophosphamide improves outcome in early breast cancer. Patients and Methods: Women with axillary node-positive or high-risk node-negative breast cancer were randomly assigned to receive either three cycles of docetaxel and capecitabine (TX) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX: n = 753) or three cycles of docetaxel (T) followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF: n = 747). The primary end point was recurrence-free survival (RFS). Results: During a median follow-up time of 59 months, 214 RFS events occurred (local or distant recurrences or deaths: TX/CEX, n = 96: T/CEF, n = 118). RFS was not significantly different between the groups (hazard ratio [HR], 0.79: 95% CI, 0.60 to 1.04: P = .087: 5-year RFS, 86.6% for TX/CEX v 84.1% for T/CEF). Fifty-six patients assigned to TX/CEX died during the follow-up compared with 75 of patients assigned to T/CEF (HR, 0.73: 95% CI, 0.52 to 1.04: P = .080). In exploratory analyses, TX/CEX improved breast cancer-specific survival (HR, 0.64: 95% CI, 0.44 to 0.95: P = .027) and RFS in women with triple-negative disease and in women who had more than three metastatic axillary lymph nodes at the time of diagnosis. We detected little severe late toxicity. Conclusion: Integration of capecitabine into a regimen that contains docetaxel, epirubicin, and cyclophosphamide did not improve RFS significantly compared with a similar regimen without capecitabine.

Original languageEnglish
Pages (from-to)11-18
Number of pages8
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume30
Issue number1
DOIs
Publication statusPublished - 2012
Publication typeA1 Journal article-refereed

Publication forum classification

  • Publication forum level 3

Fingerprint

Dive into the research topics of 'Adjuvant capecitabine, docetaxel, cyclophosphamide,and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial'. Together they form a unique fingerprint.

Cite this